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Abstract
Objectives:	To	determine	the	relevance	of	Mini-	Mental	State	Examination	 (MMSE),	
serum	25-	hydroxyvitamin	D	 (25(OH)D3),	 and	 1,25(OH)2D3	 concentrations	 to	mild	
cognitive	impairment	(MCI)	and	various	stages	of	Alzheimer’s	disease	(AD).
Materials and Methods: The study included 230 participants (>74 years) allocated to 
three	main	groups:	1-	healthy	subjects	(HS,	n	=	61),	2-	patients	with	MCI	(n	=	61),	and	
3-	patients	with	Alzheimer’s	disease	(AD)	subdivided	into	three	stages:	mild	(n	=	41),	
moderate (n	=	35),	and	severe	AD	(n = 32). The cognitive status was evaluated using 
MMSE.	Serum	25	(OH)D3	(ng/ml)	and	1,25(OH)2D3	concentrations	(pg/ml)	were	de-
termined by competitive radioimmunoassay.
Results:	MMSE	scores	and	25(OH)D3	were	decreased	in	MCI	and	all	stages	of	the	AD	
in	both	genders.	MMSE	variability	was	due	to	gender	in	HS	(11%)	and	to	25(OH)D3	in	
MCI	(15%)	and	AD	(26%).	ROC	analysis	revealed	an	outstanding	property	of	MMSE	in	
diagnosis	of	MCI	(AUC,	0.906;	CI	95%,	0.847–0.965;	sensitivity	82%;	specificity,	98%)	
and	AD	(AUC,	0.997;	CI	95%,	0.992–1;	sensitivity,	100%;	specificity,	98%).	25(OH)D3	
exhibited	good	property	 in	MCI	 (AUC,	0.765;	CI	95%,	0.681–0.849;	sensitivity,	90%;	
specificity,	54%)	and	an	excellent	property	 in	diagnosis	of	AD	 (AUC,	0.843;	CI	95%,	
0.782–0.904;	sensitivity,	97%;	specificity,	79%).	Logistic	analyses	revealed	that,	in	MCI,	
MMSE	could	predict	(or	classify	correctly)	with	97.6%	accuracy	(Wald,	15.22,	β,	−0.162;	
SE,	0.554;	OR	=	0.115:0.039–0.341;	p	=	.0001),	whereas	25(OH)D3	with	80%	accuracy	
(Wald,	41,013;	β,	−0.213;	SE,	0.033;	OR	=	0.808:	0.757–863;	p	=	.0001).	25(OH)D3	was	
the	only	significant	predictor	for	the	severe	AD	and	contributed	to	MMSE	variability.	
Age	and	gender	were	significant	predictors	only	in	the	moderate	AD.	In	patients	with	
MCI,	25(OH)D3	and	1,25(OH)2D3	were	correlated	men,	but	 in	case	of	the	AD,	they	
were correlated in women.
Conclusions:	MMSE	and	serum	25(OH)D3	concentrations	could	be	useful	biomarkers	
for	prediction	and	diagnosis	of	MCI	and	various	stages	of	the	AD.	The	results	support	
the	utility	of	vitamin	D	supplementation	in	AD	therapy	regimen.
K E Y W O R D S
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1  | INTRODUCTION
Alzheimer’s	disease	(AD)	is	the	most	common	cause	of	cognition	im-
pairment	in	elderly	populations.	AD	is	characterized	by	dementia	with	
progressive	 loss	 of	memory,	 intellectuality,	 disturbance	 of	 language	
ability,	impairment	in	social	performance,	and	reduced	independence	
(i.e.,	the	need	for	caregiver	support	in	daily	life).	Although	a	definitive	
diagnosis	of	AD	can	only	be	made	based	on	histopathological	examina-
tion	of	brain	specimens,	the	clinical	diagnosis	of	AD	could	have	a	high	
degree of accuracy if dementia is diagnosed using a cognitive score 
(Creavin	et	al.,	2016;	Votruba,	Persad,	&	Giordani,	2016).	 In	addition	
to	 age	 and	 gender,	 the	Mini-	Mental	 State	Examination	 (MMSE)	 has	
been regarded as a useful instrument for evaluating the cognitive state 
of	patients	 (Folstein,	Folstein,	&	McHugh,	1975)	and	used	as	a	pre-
dictor	of	AD	(Musicco	et	al.,	2009).	Mild	cognitive	 impairment	(MCI)	
is	 subclinical	complaint	of	memory	 function	 in	elderly	people.	 It	has	
been	reported	that	10%–20%	of	individuals	over	the	age	of	65	years	
suffer	from	MCI	(Petersen,	2011),	with	high	potential	of	converting	to	
AD	(Devanand	et	al.,2008;	Ganguli	et	al.,	2011;	Petersen	et	al.,	2001;	
Ritchie	&	Touchon,	2000).
In	 addition	 to	 its	 known	 significance	 in	 bone	 and	 calcium	 ho-
meostasis,	vitamin	D	 improves	protein	homeostasis	and	slows	aging	
(Mark	et	al.,	2016).	The	enzymes	involved	in	conversion	of	25(OH)D3 
to	1,25(OH)2D3	 are	 all	 present	 in	 the	brain	 (Harms,	Burne,	 Eyles,	&	
McGrath,	2011).	There	is	a	reciprocal	relationship	between	vitamin	D	
and	AD.	It	has	been	reported	that	25(OH)D3 is reduced in late- onset 
AD,	and	vitamin	D	deficiency	is	regarded	as	a	risk	factor	for	ApoEε4 
noncarrier	patients	with	AD	(Dursun	et	al.,	2016).	On	the	other	hand,	
supplementation	with	vitamin	D	derivatives	decreases	the	risk	of	AD	
(Dean,	Bellgrove,	&	Hall,	2011).	It	has	recently	been	found	that	vita-
min	D	receptors	are	colocalized	with	amyloid	precursor	protein	on	the	
neuronal	 plasma	membrane	 (Dursun	&	Gezen-	Ak,	 2017).	Amyloid	β 
(Aβ),	 the	 pathological	 hallmark	 of	AD,	 degrades	 vitamin	D	 receptor	
(Dursun,	Gezen-	Ak,	&	Yilmazer,	2010).	Vitamin	D	decreases	the	bur-
den	of	major	pathological	aggregates	in	AD,	including	Aβ plaques and 
hyperphosphorylated	tau	protein	(Durk,	Han,	&	Chow,	2014;	Yu	et	al.,	
2011)	and	augments	activity	of	memantine	 in	AD	 (Lemire,	Brangier,	
Beaudenon,	Duval,	&	Annweiler,	2016).	Moreover,	many	reports	sug-
gest	a	relationship	between	vitamin	D	deficiency	with	MCI	(Annweiler	
et	al.,	2012;	Yin,	Fan,	Lin,	Xu,	&	Zhang,	2015)	and	AD	(Annweiler	et	al.,	
2010,	2011;	Landel,	Annweiler,	Millet,	Morello,	&	Féron,	2016;	Nissou	
et	al.,	2014;	Schlögl	&	Holick,	2014).
There	are	several	measures	 that	could	distinguish	AD	from	con-
trol subjects. These include decreased metabolism of fluorodeoxy-
glucose	 (Silverman	 et	al.,	 2001),	 increased	 uptake	 of	 amyloid	 (Small	
et	al.,	 2006),	 elevated	 levels	 of	 tau	 or	 its	 phosphorylated	 form,	 and	
decreased amyloid β42	 in	 CSF	 (Hansson	 et	al.,	 2006;	 Querfurth	 &	
LaFerla,	2010;	Sunderland	et	al.,	 2003).	However,	 these	approaches	
are	either	 invasive	or	very	expensive.	Therefore,	 there	 is	still	a	need	
for developing diagnosis as well as treatment approaches to diseases 
characterized	by	dementia.	Also,	as	to	our	knowledge,	no	study	of	pos-
sible	use	of	both	25(OH)D3	and	1,25(OH)2D3,	separately	or	in	combi-
nation	with	MMSE,	as	predictors	 in	diagnosis	and	prediction	of	MCI	
and	various	 stages	 (mild,	moderate,	 and	 severe)	 of	AD.	Accordingly,	
this	study	was	conducted	to	evaluate	utility	of	MMSE,	serum	25(OH)
D3,	and	1,25(OH)2D3 concentrations in prediction and diagnosis pa-
tients	with	MCI	and	the	various	stages	of	AD.
2  | MATERIALS AND METHODS
2.1 | Participants
A	total	of	230	individuals	from	Fukuoka	University	Hospital	were	in-
cluded in this study. The participants were allocated to three groups: 
I-	Healthy	subjects	(HS),	II-	patients	with	MCI	and	III-	patients	with	AD	
main	group	classified,	according	to	disease	severity,	into	three	stages	
defined	as	1-	mild	AD,	2-	moderate	AD,	and	3-	severe	AD.	Diagnosis	of	
MCI	was	performed	according	to	Petersen’s	criteria	(Petersen,	2011;	
Petersen	et	al.,	2001;	Ritchie	&	Touchon,	2000).	The	severity	of	cog-
nitive	 impairment	 in	 patients	 with	 AD	was	 evaluated	 using	MMSE	
scores:	mild	AD	(27	≥	MMSE	>	20),	moderate	AD	(20	≥	MMSE	>	10),	
and	 severe	 AD	 (10	>	MMSE)	 (Feldman,	 Van	 Baelen,	 Kavanagh,	 &	
Torfs,	2005;	O’Bryant,	Humphreys,	&	Smith,	2008).	Each	participant	
was clinically evaluated by set of tests that included questionnaire and 
a	proxy	interview,	assessment	of	past	and	present	illness,	neurological	
and	physical	 examinations,	blood	chemistry,	 and	neuroimaging	with	
computed tomography and/or magnetic resonance imaging. Some 
participants	in	the	HS	group	had	hypertension	(eight	of	33;	24%)	and/
or	hypercholesterolemia	(four	of	33;	12%),	regarded	above	the	base-
line	blood	pressure	(systolic	139/diastolic	89	mmHg)	and	cholesterol	
(219	mg/dl).	All	groups	were	gender-	balanced	except	there	were	two	
times	as	many	women	as	men	in	the	moderate	and	severe	AD	groups.	
Moreover,	the	groups	were	also	age-	matched	except	the	difference	
between	women	moderate	AD	compared	to	women	HS	(p = .23) and 
men	HS	(p = .013). The respective ages (year) of women and men were 
as	follows:	HS	(74.5	±	6.3;	74.4	±	8.7),	MCI	(75.5	±	6.8,	77.7	±	11.2),	
mild	AD	(74.8	±	8.1;	78.3	±	6.3),	moderate	AD	(82.2	±	5.1;	76.9	±	7.6),	
and	 severe	 AD	 (77.7	±	8.7;	 76.5	±	9.1).	 A	 difference	 was	 detected	
only	between	moderate	AD	women	and	HS	women	(p = 0.031),	and	
between	 moderate	 AD	women	 and	 moderate	 AD	men	 (p = 0.016). 
This difference is consequent to grouping according to the clinical 
classification	to	MCI	or	AD.	All	participants	were	free	of	hepatic	and	
renal disorders. The ethical permission for this study was obtained 
from	the	ethical	committee	of	Fukuoka	University	Hospital.	The	study	
was performed in accordance with the ethical standards of the 1964 
Helsinki	Declaration.	Written	informed	consent	was	obtained	from	all	
participants or their relatives prior to their participation in the study. 
We excluded participants with any present or earlier history of vita-
min	D	supplementation.
2.2 | Samples preparations and analyses
Peripheral blood was collected from each participant and cen-
trifuged at 400 x g for 20 min. The sera obtained were stored at 
−80°C	 until	 use.	 Total	 serum	 concentrations	 of	 25(OH)D3 and 
1,25(OH)2D3 were determined by competitive radioimmunoassay 
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using	 two	 respective	 antibodies.	A	 25-	OH	 vitamin	D	 125I	 RIA	Kit	
(DiaSorin	Inc.	MN,	USA)	was	used	to	assay	25(OH)D3.	Briefly,	after	
pretreatment of the samples with acetonitrile 300 to remove pro-
teins,	 the	 sample	 extracts	 containing	 25(OH)D3 were incubated 
with 125I-	25(OH)D3	and	sheep	anti-	25(OH)D3 antibody for 90 min 
at	 room	 temperature.	 Cellulose-	conjugated	 anti-	sheep	 IgG	 anti-
body was added to the precipitated reactive complex and free 125I-	
25(OH)D3 was removed by centrifugation. The radioactivity in each 
precipitate was assayed using a γ-	counter	(ARC-	950,	Hitachi-	Aloka	
Medical	Ltd,	Japan),	and	concentrations	were	determined	accord-
ing	to	a	standard	curve.	A	1,25(OH)2D3	RIA	Kit	(Immunodiagnostic	
Systems	Ltd,	Boldon,	England)	was	used	to	assay	1,25(OH)2D3. The 
principle of this assay system was the same as that above except a 
column technique was also employed to remove lipids during sam-
ple pretreatment.
2.3 | Statistical analyses
ANOVA	 one-	way	 was	 conducted	 on	 the	 variables	 (age,	 MMSE,	
25(OH)D3	 and	 1,25(OH)2D3)	 between	 groups	 (HS,	 MCI,	 mild	 AD,	
moderate	 AD	 and	 severe	 D),	 with	 gender	 as	 covariate,	 to	 detect	
the	 following:	 1-	the	main	 effect,	 differences	 between	 the	 variables	
of	 the	groups,	2-	The	groups	within	each	gender,	and	each	gender’s	
variable between groups were compared to evaluate the effects of 
gender.	Homogeneity	was	verified.	Tukey’s	multiple	comparisons	post	
hoc	 test	was	 applied	whenever	ANOVA	detected	 significant	differ-
ences.	Bivariate	correlations	among	the	variables	were	evaluated	by	
Pearson’s	correlation	coefficient.	As	MMSE	could	be	seen	as	both	risk	
factor	 and	outcome	of	 the	disease,	 a	 linear	 regression	 analysis	was	
also	 conducted	 to	 determine	 the	 regression	 coefficients,	 statistical	
significance of regression model (t	 value),	 and	proportion	of	MMSE	
(dependent)	 contributed	 by	 independent	 variables	 (age,	 gender,	
25(OH)D3,	 and	1,25(OH)2D3)	derived	 from	 the	multiple	 correlation	
coefficient	(Adjusted	R2).
The predictors were also tested with univariate logistic regression 
analyses to assess the contribution of each predictor alone to each 
group.	Then,	multivariate-	forward	selection	analyses	were	conducted	
to assess the contribution of the predictors in combination to in-
crease the statistical power and account for the individual differences 
in	prediction.	Variables	which	had	a	p value of >.05 were excluded. 
The followings were calculated: β: logistic regression coefficient de-
scribes	the	size	and	direction	of	the	relationship	between	a	predic-
tor and the disease (predictive value). Positive predictive value is the 
probability that a subject classified as a patient by the test belongs 
in the patient group becomes more likely as the predictor increases. 
Negative	predictive	value	is	the	probability	that	a	subject	classified	as	
a	nonpatient	by	the	test	belongs	in	the	nonpatient	group.	It	also	indi-
cates the inverse relationship between the predictor and the disease 
(decreased	predictor	means	 increased	disease	odd).	Odd	ratio	 (OR):	
the	ratio	of	the	odds,	calculated	as	the	exponent	of	β.	OR	is	the	mea-
surement of likelihood and indicates that when the predictor is raised 
by one unit the odds ratio of the outcome increase by a factor equal 
to	 the	OR	value,	 that	 is,	 the	odds	of	participants	 in	 the	dependent	
variable	 (patients)	 increase	by	a	 factor	equivalent	 to	OR	value	with	
95%	confidence	interval	(CI).	Correct	classification,	CC	(accuracy	rate	
(%)	 of	 the	 predictor	 to	 diagnose	or	 distinguish	 two	 compared	vari-
ables),	 and	Wald	value	 (significance	of	predictor	 contribution)	were	
also measured.
Receiver	operating	characteristic	(ROC)	analysis	provides	useful	
information regarding the ability of a predictor to classify subjects 
into	the	relevant	groups,	and	to	compare	the	performance	of	more	
than	one	predictor.	ROC	was	conducted	to	calculate	area	under	the	
ROC	curve	(AUC),	sensitivity,	and	specificity.	Cutoff	values	at	which	
optimal balance of sensitivity and specificity can be obtained were 
derived	 according	 to	Youden	 Index.	 Sensitivity	 (with	 optimal	 95%	
confidence interval) is the probability that a test result will be posi-
tive when the disease is present (true positive rate—the probability 
that a patient will be accurately classified by the test). Specificity 
(with	optimal	95%	confidence	interval)	 is	probability	that	a	test	re-
sult will be negative when the disease is not present (true negative 
rate—the probability that a nonpatient will be accurately classified 
by	the	test).	The	AUC	is	a	measure	of	the	efficacy	of	the	test.	The	
AUC	values	are	typically	interpreted	as	chance	(0.0–0.4),	poor	(0.5–
0.6),	weak	(0.6–0.7),	good	or	acceptable	(0.7–0.8),	excellent	or	great	
(0.8–0.9),	and	perfect	or	outstanding	(0.9–1.0).	The	higher	the	AUC,	
the	more	 true	 positive	 is	 the	 result.	 The	 positive	 (LR+)	 and	 nega-
tive	 (LR−)	 likelihood	 ratios	 are	 probabilities	 of	 respective	 positive	
and negative test results. They can be derived from sensitivity and 
specificity:	LR+	=	(Sensitivity	or	True	positive/1	−	Specificity	or	False	
positive);	LR−	=	(1	−	Sensitivity	or	False	negative/Specificity	or	True	
negative).
The criterion for statistical significance was p < .05. The values are 
presented	as	the	mean	±	standard	deviation	in	Figures	1–3,	and	as	the	
standard	error	in	the	tables.	The	data	were	analyzed,	using	IBM	SPSS	
Statistics version 23.
3  | RESULTS
3.1 | MMSE scores in patients with MCI and AD
The	MMSE	scores	of	HS	women	and	men	were	28.0	±	1.9,	29.1	±	0.9,	
respectively.	 Figure	1	 shows	 that	MMSE	 scores	 were	 decreased	 in	
MCI	 and	AD.	A	 significant	 difference	 for	 the	main	 effect,	 between	
groups,	was	detected	for	MMSE	(F(4,225)	=	722.076;	p = .000). There 
was	no	difference	in	the	MMSE	values	between	women	(26.0	±	2.4)	
and	men	(26.0	±	1.8)	with	MCI.	The	MMSE	scores	were	decreased	in	
mild	AD	(women	23.9	±	2.0,	men	23.2	±	1.6),	moderate	AD	(women	
16.1	±	2.5,	men	 17.5	±	2.0),	 and	 severe	 AD	 (women	 4.6	±	4.1,	men	
4.5	±	3.4).	The	decrease	 in	MMSE	scores	 in	AD	was	more	than	that	
observed	in	MCI	 in	both	genders	(p = .000 for moderate and severe 
AD	vs.	MCI)	except	 in	mild	AD	 (women,	p = .030;	men,	p = .002 vs. 
MCI).	 In	 addition,	 significant	 differences	 (p = .000) were detected 
among	the	various	stages	of	AD	in	women	and	men	analyzed	sepa-
rately.	 However,	 no	 significant	 gender-	dependent	 difference	 was	
detected	for	the	same	stage	of	AD	between	women	and	men	when	
compared to each other.
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3.2 | Serum 25(OH)D3 concentrations in patients 
with MCI and AD
In	 HS,	 the	 mean	 serum	 concentrations	 of	 25(OH)D3 were 
26.18	±	7.18	ng/ml	 and	 27.42	±	8.05	ng/ml	 in	 women	 and	 men	
	participants,	 respectively.	 A	 significant	 (F(4,225)	=	25.869,	
p = .000)	main	 effect	 of	25(OH)D3	was	obtained	 in	MCI	 and	AD.	
Figure	2	shows	that	concentrations	of	25(OH)D3 in patients with 
MCI	 were	 lower	 than	 HS	 in	 both	 women	 (18.23	±	5.11	ng/ml;	
p = .000)	 and	 men	 (21.03	±	6.99	ng/ml;	 p = .003).	 However,	 the	
concentrations	 of	 25(OH)D3	 in	MCI	were	 not	 different	 from	AD	
in both genders.
Figure	2a	 shows	 that	 in	 AD	 women	 patients,	 25(OH)D3 con-
centrations	 in	 mild	 AD	 (17.75	±	5.30	ng/ml),	 moderate	 AD	
(16.79	±	5.32	ng/ml),	 and	 severe	 AD	 (13.95	±	5.08	ng/ml)	 were	
significantly	lower	than	HS	(p = .000).	On	the	other	hand,	it	can	be	
seen	 from	 Figure	2b	 that	 in	 the	men	 patients,	 the	 concentrations	
of	25(OH)D3 were significantly (p = .000)	lower	than	HS	in	mild	AD	
(17.59	±	6.95	ng/ml)	and	severe	AD	(15.36	±	4.08	ng/ml).	However,	
no significant (p = .105)	difference	was	detected	between	HS	and	
the	 moderate	 AD	 (21.09	±	6.32	ng/ml).	 No	 significant	 difference	
was	detected	among	the	AD	stages	for	the	same	gender,	or	between	
the genders in each group.
3.3 | Serum 1,25(OH)2D3 concentrations in patients 
with MCI and AD
In	 HS,	 the	 mean	 serum	 concentrations	 of	 1,25(OH)2D3 were 
53.05	±	13.04	pg/ml	 and	 54.12	±	14.34	pg/ml	 in	 women	 and	 men	
participants,	 respectively.	 Figure	3a	 shows	 that,	 in	 women,	 the	
concentrations	 of	 1,25(OH)2D3	 were	 55.38	±	22.85	pg/ml	 (MCI),	
62.53	±	17.03	pg/ml	 (mild	AD),	54.22	±	13.71	pg/ml	 (moderate	AD),	
and	61.84	±	26.45	pg/ml	(severe	AD).	Moreover,	Figure	3b	shows	that,	
in	men,	the	concentrations	of	1,25(OH)2D3	were	55.01	±	18.00	pg/ml	
(MCI),	53.52	±	19.20	pg/ml	(mild	AD),	57.02	±	15.03	pg/ml	(moderate	
AD),	 and	 48.25	±	9.55	pg/ml	 (severe	 AD).	 No	 significant	 difference	
among the groups was detected (F(4,225)	=	0.583,	p = .676).
3.4 | Correlations among MMSE, 25(OH)D3, and 
1,25(OH)2D3
Table	1	 and	 Figure	4	 show	 that	 no	 correlation	 was	 evident	 in	 HS.	
On	 the	 other	 hand,	 in	 MCI,	 the	 largest	 and	 significant	 correlation	
was	detected	in	men	between	25(OH)D3	and	1,25(OH)2D3 (r	=	.456,	
p = .011)	in	addition	to	the	correlation	between	25(OH)D3 and MMSE 
(r	=	.330,	p = .022),	and	1,25(OH)	2D3 (r	=	−.356,	p = .048). The total 
correlation	between	25(OH)D3	and	1,25(OH)2D3	in	both	genders	was	
F IGURE  1 Box	plot	of	MMSE	scores	
in women (a) and men (b). The lower and 
upper sides of the boxes indicate the 
25th	and	75th	percentiles.	The	horizontal	
lines and black diamonds inside the 
boxes	indicate	the	median	and	means,	
respectively. Shown are also the lower and 
upper whiskers that indicate the minimum 
and	maximum	values,	respectively.	In	
women	HS,	the	upper	horizontal	bar	
outside the box with the whisker and 
the median line inside the box have not 
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F IGURE  2 Box	plot	of	serum	
concentrations	of	25(OH)D3 in women (a) 
and	men	(b)	HS,	MCI	and	AD.	The	lower	
and upper sides of the boxes indicate the 
25th	and	75th	percentiles.	The	horizontal	
lines and black diamonds inside the 
boxes	indicate	the	median	and	means,	
respectively. Shown are also the lower and 
upper whiskers that indicate the minimum 
and	maximum	values,	respectively.	The	
levels of statistically significant differences 
are	indicated	over	each	point.	Alzheimer’s	
disease	(AD)	and	mild	cognitive	impairment	
(MCI)	compared	with	healthy	subjects	(HS)
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F IGURE  3 Box	plot	of	serum	
concentrations	of	1,25(OH)D3 in women 
(a) and men (b). The lower and upper sides 
of the boxes indicate the 25th and 75th 
percentiles.	The	horizontal	lines	and	black	
diamonds inside the boxes indicate the 
median	and	means,	respectively.	Shown	
are also the lower and upper whiskers 
that indicate the minimum and maximum 
values,	respectively.	No	significant	
differences were detected among healthy 
subjects	(HS),	patients	with	mild	cognitive	
impairment	(MCI),	and	patients	with	
Alzheimer’s	disease	(AD)
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significant (r	=	.254,	p = .05).	No	significant	correlation	was	observed	
in	women	with	MCI.
In	patients	with	AD,	significant	correlations	were	detected	only	
in	 women.	 MMSE	was	 correlated	 only	 with	 25(OH)D3 in moder-
ate	 AD	 (r	=	−.326,	 p = .048)	 and	 severe	 AD	 (r	=	−.331,	 p = .023),	
indicating	to	a	parallel	decrease	of	MMSE	with	25(OH)D3,	but	not	
1,25(OH)2D3.	 On	 the	 other	 hand,	 the	 largest	 correlation	was	 de-
tected	between	25(OH)D3	and	1,25(OH)2D3	 in	severe	AD	(r = .62; 
p = .003)	 followed	 by	 mild	 AD	 (r	=	.487,	 p = .016). There was no 
significant	 correlation	 between	 25(OH)D3	 and	 1,25(OH)2D3 in 
moderate	AD	(r	=	.357,	p = .087).	The	correlation	of	25(OH)D3 and 
1,25(OH)2D3 values of all stages together was significant in women 
(r	=	.488,	p = .016) but not in men (r	=	.114,	p = .710). The total cor-
relation	between	25(OH)D3	and	1,25(OH)2D3 for both genders was 
not significant (r	=	.301,	p = .372).
The linear regression established that only gender could signifi-
cantly predict MMSE (B	=	0.325,	t	=	2.638,	p = .011) and account for 
11%	(adjusted	R2)	of	MMSE	variability	 in	HS.	On	the	other	hand,	al-
though	both	25(OH)D3	and	1,25(OH)2D3 contributed to MMSE vari-
ability	in	MCI,	1,25(OH)	2D3	accounted	for	only	3%	of	the	variability	
(p = .075),	while	25(OH)D3 significantly (p = .0001)	contributed	(16%)	
to	MMSE	variability.	On	the	other	hand,	in	AD,	only	25(OH)D3 could 
significantly (p = .000)	affect	MMSE	and	accounts	for	26%	of	MMSE	
variability (Table 2).
3.5 | Receiver operating characteristic (ROC) analysis
Table	3	shows	that	MMSE	displayed	an	excellent–perfect	diagnostic	
power	and	differentiating	MCI	from	HS,	various	AD	stages	among	
themselves	and	each	stage	from	HS.	However,	MMSE	exhibited	the	
same or close sensitivity and specificity values. The highest cutoff 
value	 was	 obtained	 in	 MCI	 and	 AD	 when	 evaluated	 against	 HS.	
Moreover,	higher	LR+	and	lower	LR−	for	MMSE	were	observed	in	
MCI	and	mild	AD	combined	with	HS	(data	not	shown).	On	the	other	
hand,	 an	 excellent–perfect	 differential	 diagnostic	 power	 was	 de-
tected	for	25(OH)D3	when	either	MCI	or	AD	subgroups	were	evalu-
ated	against	HS.	However,	25(OH)D3	exhibited	poor–weak	power	
when	the	differential	diagnosis	was	analyzed	among	the	stages	of	
AD.	Moreover,	 high	 sensitivity	 and	 low	 specificity	were	 obtained	
for	25(OH)D3	especially	in	MCI	and	AD	when	evaluated	against	HS.	
The	cutoff	value	of	25(OH)D3	was	higher	than	MMSE,	especially	in	
patients	with	AD	whether	evaluated	against	HS	or	other	groups	of	
AD.	Moreover,	 higher	 (10	 times)	 LR+	 than	 LR−	was	 observed	 for	
25(OH)D3	(data	not	shown).
TABLE  1 Correlations	among	MMSE,	25	(OH)D3	and.	1,25(OH)2	D3	in	healthy	subjects	(HS)	and	patients	with	mild	cognitive	impairment	
(MCI)	and	Alzheimer’s	diseases	(AD)
Women 25 (OH)D3 1,25 (OH)2 D3 Men 25 (OH)D3 1,25 (OH)2 D3
HS	(n = 28) MMSE r .122 .147 HS	(n = 33) MMSE r −.139 −.134
p .535 .258 p .441 .457
25(OH)D3 r 1 −.041 25(OH)D3 r 1 −.248
p — .836 p — .165
MCI	(n = 31) MMSE r −.016 −.288 MCI	(n = 30) MMSE r .330 −.365
p .932 .115 p .022* .048*
25(OH)D3 r 1 .082 25(OH)D3 r 1 .456
p — .66 p — .011*
Mild	AD	
(n = 24)
MMSE r −.086 −.099 Mild	AD	
(n = 17)
MMSE r .052 −.275
p .689 .645 p .842 .285
25(OH)D3 r 1 .487 25(OH)D3 r 1 .163
p — .016* p — .531
Moderate	AD	
(n = 24)
MMSE r −.326 .148 Moderate	AD	
(n = 11)
MMSE r −.415 −.280
p .048* .49 p .205 .404
25(OH)D3 r 1 .357 25(OH)D3 r 1 .156
p — .087 p — .647
Severe	AD	
(n = 21)
MMSE r −.331 .239 Severe	AD	
(n = 11)
MMSE r .138 .056
p .023* .297 p .687 .87
25(OH)D3 r 1 .62 25(OH)D3 r 1 .024
p — .003* p — .944
The correlation coefficient magnitude (r)	is	determined	according	to	Pearson’s	correlation:	small	(r	=	.1),	medium	(r	=	.3),	and	large	(r = >.5).
*Significant correlation.
     |  7 of 12OUMA et Al.
3.6 | Univariate and multivariate logistic 
regression analyses
The	prediction	values	were	evaluated	for	each	of	MCI	and	AD	groups	
against	 HS.	 Univariate	 analysis	 of	 each	 predictor	 alone	 (Table	4)	
shows that significant (p = .0001) prediction by age (β	=	+0.133;	
Wald	=	12.12;	 OR	=	1.143;	 CC	=	71%;	 p = .0001) and gender 
(β	=	−0.944;	Wald	=	4.49;	OR	=	0.389;	 CC	=	64%;	p = .034) was ob-
tained	in	moderate	AD.	These	results	indicate	that	for	each	one	unit	
increase	of	age	(1	year),	the	odds	of	disease	risk	 increases	by	1.143	
(53%	 probability).	 In	 case	 of	 gender,	 women	 were	 considered	 as	
the	reference.	In	other	words,	the	negative	value	of	β indicates that 
women have 2.6 (1/0.389 = 2.6) times the risk of the disease than 
men.	Moreover,	 it	 can	 also	 be	 seen	 from	 Table	4	 that	 a	 significant	
(p	=	.0001)	 prediction	 by	MMSE	was	 observed	 in	MCI	 (β	=	−1.324,	
Wald	=	27.86,	OR	=	0.266)	 and	mild	 AD	 (β	=	−2.162,	Wald	=	15.22,	
OR	=	0.115).	These	results	indicate	that	each	unit	decrease	of	MMSE	
reflects	21%	and	13%	probability	 increase	 in	the	prediction	odds	of	
MCI	and	mild	AD,	respectively.	Table	4	also	shows	that	the	higher	OR	
and	Wald	 values	were	 detected	 for	 25(OH)D3	 in	MCI	 (β	=	−0.146,	
Wald	=	22.044,	 OR	=	0.864,	 46%	 probability),	 mild	 AD	 (β	=	−0.188,	
Wald	=	22.744,	 OR	=	0.829,	 45%	 probability),	 moderate	 AD	
(β	=	−0.178,	Wald	=	20.04,	OR	=	0.837,	46%	probability),	and	severe	
AD	(β	=	−0.316,	Wald	=	20.821,	OR	=	0.729,	42%).	These	results	indi-
cate	that	each	unit	decrease	of	25(OH)D3 reflects an increase in the 
prediction	OR	(by	about	80%)	and	probability	 (>40%)	rate	 indicated	
for	each	of	MCI	and	AD	groups.	Multivariate	analysis	of	all	predictors	
combined	within	each	group	revealed	that	only	MMSE	and	25(OH)D3 
displayed	significant	prediction	of	MCI.
Table 4 shows that univariate analysis of all groups collectively re-
vealed the significant contribution of all the examined predictors. The 
maximum	Wald	(41.013)	and	CC%	(97.6%)	were	exhibited	by	25(OH)
D3	and	MMSE,	respectively.	Again,	multivariate	analysis	showed	that	
only	combined	MMSE	and	25(OH)D3 retained their significant predic-
tion	and	exhibited	98%	accuracy	in	distinguishing	and	predicting	the	
diseases.
4  | DISCUSSION
The	 present	 results	 show	 that	 MMSE	 and	 25(OH)D3 (but not 
1,25(OH)2D3)	 were	 decreased	 in	 MCI	 and	 various	 stages	 of	 AD.	
Although	MMSE	is	one	of	the	most	widely	used	tools	in	the	evaluation	
of	cognitive	status,	there	is	still	a	debate	about	its	diagnostic	accuracy.	
Some studies have reported that MMSE lacks diagnostic specificity 
and	has	limited	diagnostic	accuracy,	particularly	for	distinguishing	be-
tween	normal	cognition	and	MCI,	and	MCI	 from	demential	patients	
with	AD	(Chapman	et	al.,	2016)	and	in	measuring	the	progression	of	
Alzheimer’s	disease	(Clark	et	al.,	1999).	On	the	other	hand,	MMSE	has	
been regarded as a good first step in the evaluation of cognitive sta-
tus	and	effectively	separating	those	with	mild	AD	from	normal	aging	
and	MCI	(Benson,	Slavin,	Tran,	Petrella,	&	Doraiswamy,	2005).	It	has	
high	test–retest	reliability	values,	ranging	from	0.79	to	0.99	(Folstein	T
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et	al.,	1975).	MMSE	had	also	been	reported	to	predict	converters	to	
AD	(Devanand	et	al.,	2008;	Palmqvist	et	al.,	2012).	The	present	study	
highlights	the	value	of	MMSE	and	25(OH)D3 in the differential diag-
nosis	and	prediction	of	MCI,	mild	AD,	moderate	AD,	and	severe	AD	
at a sensitivity rate >80. The differences among the results reported 
for MMSE could be attributed to the analyses approach such as selec-
tion	of	the	cutoff	values,	and	the	patients’	cultural,	education,	and	de-
mographic	specificities.	It	is	also	noteworthy	to	mention	that	MMSE	
could	be	 influenced	by	 changes	 that	 could	 accompany	dementia.	A	
low level of the MMSE score is associated with low plasma phosphate 
(Haglin	&	Backman,	2016).
Vitamin	D3	 is	produced	 in	 the	skin	 from	7-	dehydrocholesterol	
under	 the	 influence	of	UV	 light.	Vitamin	D	 is	metabolized	 first	 to	
25(OH)D3	 in	 the	 liver,	 then	 undergoes	 1α- hydroxylation to the 
hormonal	 form	1,25(OH)2D3	 in	 the	 kidney	 (Bikle,	 2014).	The	 rela-
tion	 of	 25(OH)D3	 and	 1,25(OH)2D3 is farther than that between 
a	 substrate	 and	 its	 product.	 25(OH)D3	 and	 1,25(OH)2D3 are syn-
thesized,	 regulated,	 and	 changed	 differently	 in	 variable	 diseases.	
While	 25(OH)D3	 is	 mainly	 synthesized	 by	 CYP2R1	 (endoplasmic	
reticulum),	CYP27B1	 (mitochondrial)	 is	 the	main	 enzyme	 involved	
in	the	synthesis	of	1,25(OH)2D3.	The	independence	of	1,25(OH)2D3 
concentration	from	that	of	its	precursor	(25(OH)D3) is expected and 
could be attributed to their different kinetics and regulation. While 
25(OH)D3 (prehormone) concentration is increased by a high dose 
of	vitamin	D,	plasma	levels	of	1,25(OH)2D3 (adaptive hormone) ap-
peared	 to	 fall	with	 increasing	doses	of	vitamin	D,	 presumably	be-
cause	 the	1-	hydroxylase	 system	 is	 shut	 down	 (Jones,	 Strugnell,	&	
DeLuca,	1998).	1,25(OH)2D3 inhibits its own synthesis and that of 
its	precursor	25(OH)D3	(Bell,	Shaw,	&	Turner,	1984).	It	has	been	re-
ported	that	1,25(OH)2D3 kinetics do not change by aging in healthy 
men	 and	women	 (Eastell	 et	al.,	 1991;	Halloran,	 Portale,	 Lonergan,	
&	Morris,	1990).	The	production	of	1,25(OH)2D3	could	take	place	
extrarenally	and	regulated	endocrinologically.	 It	has	been	reported	
that	 1,25(OH)2D3 is increased by parathyroid hormone (Eastell 
et	al.,	1991)	and	cytokines,	 including	TNF	(Bikle	&	Vitamin,	2014).	
However,	serum	25(OH)D3	is	negatively	correlated	with	TNFα,	IL-	1β 
or	 IL-	6	 levels	 in	healthy	subjects	and	patients	with	MCI,	but	posi-
tively	with	late-	onset	AD	(Dursun	et	al.,	2016).	As	TNF	is	increased	
in	AD	(Gezen-	Ak	et	al.,	2013),	it	is	possible	that	the	increased	TNFα 
is	 responsible	 for	 the	 decreased	 25(OH)D3. These mechanisms 
could	play	a	role	in	maintaining	1,25(OH)2D3 level against reduced 
25(OH)D3.
The	serum	vitamin	D	 level	 is	associated	with	 its	activity	 in	 the	
brain.	 Serum	 25(OH)D3 concentration is correlated with regional 
F IGURE  4 Correlations	between	serum	25(OH)D3	and	1,25(OH)2D3	concentrations	in	women	and	men	healthy	subjects	(HS),	mild	cognitive	
impairment	(MCI),	and	Alzheimer’s	disease	(AD).	Shown	are	also	the	total	correlation	values	for	both	genders	in	combination	(total)	in	each	group
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cerebral	 blood	 flow	 (Farid	 et	al.,	 2012),	 brain	 volume	 and	 gray	
matter	 thickness	 (Brouwer-	Brolsma	et	al.,	2015;	Buell	et	al.,	2010;	
Hooshmand,	Lökk,	&	Solomon,	2014)	and	clearance	of	aggregated	Aβ 
in	the	AD	brain	(Durk	et	al.,	2014;	Masoumi,	Goldenson,	&	Ghirmai,	
2009;	Yu	et	al.,	2011).	On	the	other	hand,	 low	serum	25(OH)D3 is 
associated	with	neuronal	damages	(Gezen-	AK,	Yilmazer,	&	Dursun,	
2014),	 MCI	 (Annweiler	 et	al.,	 2012),	 multidomain	 MCI	 (Yin	 et	al.,	
2015)	 and	 AD	 (Annweiler	 et	al.,	 2015;	 Balion,	 Griffith,	 &	 Strifler,	
2012;	 Chei	 et	al.,	 2014;	 Littlejohns,	 Henley,	 &	 Lang,	 2014).	 The	
present	 results	showed	that	25(OH)D3 is involved in the decrease 
of	MMSE,	and	predict	MCI,	mild	AD,	and	moderate	AD.	It	was	the	
only	significant	predictor	of	severe	AD.	It	differentiated	the	disease	
from	HS	at	a	sensitivity	>90%,	but	exhibited	only	a	poor–weak	diag-
nostic power when the evaluation was carried out among the stages 
of	AD.	 It	 should	be	noted	 that	although	25(OH)D3 was decreased 
in	MCI	and	AD,	no	difference	was	observed	between	women	and	
men	but	it	predicted	a	2.5	times	higher	incidence	of	AD	in	women	
than	 in	men.	This	 result	 is	 in	 line	with	 that	 reported	 1.5–3	 times	
higher	incidence	of	AD	in	women	than	the	incidence	in	men	(Baum,	
2005).	Our	results	also	showed	that	the	decrease	of	25(OH)	D3 in 
patients	with	MCI	and	AD	was	not	accompanied	by	a	similar	change	
of	1,25(OH)2D3;	 hence,	 serum	1,25(OH)2D3 concentration did not 
vary	among	HS	and	participants	with	MCI	or	AD.	No	change	 in	1,	
25(OH)2D3	adds	to	the	fact	that	concentration	of	1,25(OH)2D3 is not 
a	reliable	marker	in	AD.	Another	finding	of	this	study	was	that	serum	
1,25(OH)2D3	and	25(OH)D3 concentrations were not correlated in 
the	HS	group.	It	is	noteworthy	to	mention	that	while	25(OH)D3 and 
1,25(OH)2D3	 concentrations	were	 not	 correlated	 in	men	with	AD,	
they	were	positively	correlated	 in	women	patients	with	AD.	These	
results	may	be	associated	with	high	incidence	of	AD	in	women	and	
suggest	 gender	differences.	 It	 could	 also	 result	 from	possible	 lim-
itation	of	1,25(OH)2D3	synthesis	from	25(OH)D3 in these patients. 
These	results	could	suggest	that	vitamin	D	supplementation	may	be	
useful	to	patients	with	AD,	especially	in	women,	based	on	a	positive	
correlation	between	serum	25(OH)D3	and	1,25(OH)2D3	in	patients	
with	AD.
TABLE  3 Bivariate	receiver	operating	characteristic	(ROC)	analysis	of	the	study	groups
AUC SE Sig
CI (95%)
Cut- offa Sensitivity SpecificityLower Bound Upper Bound
MCI	vs.	HS MMSE 0.906 0.03 0.0001* 0.847 0.965 27.5 0.82 0.984
25	(OH)D3 0.765 0.04 0.0001* 0.681 0.849 27.5 0.902 0.541
1,25(OH)2	D3 0.5 0.05 1.000 0.396 0.604 — — —
Mild	AD	vs.	
HS
MMSE 0.993 0.01 0.0001* 0.979 1 27.5 1 0.984
25	(OH)D3 0.815 0.04 0.0001* 0.736 0.895 25.5 0.927 0.574
1,25(OH)2	D3 0.41 0.06 0.124 0.293 0.527 — — —
Moderate	AD	
vs.	HS
MMSE 1 0 0.0001* 1 1 22 1 1
25	(OH)D3 0.812 0.04 0.0001* 0.725 0.899 27.5 0.943 0.541
1,25(OH)2	D3 0.472 0.06 0.645 0.351 0.593 — — —
Severe	AD	vs.	
HS
MMSE 1 0 0.0001* 1 1 17 1 1
25	(OH)D3 0.911 0.03 0.0001* 0.857 0.966 20.5 0.906 0.787
1,25(OH)2	D3 0.493 0.07 0.913 0.367 0.62 — — —
Mild	AD	vs.	
Moderate 
AD
MMSE 1 0 0.0001* 1 1 20.5 1 1
25	(OH)D3 0.494 0.07 0.929 0.363 0.626 — — —
1,25(OH)2	D3 0.566 0.07 0.327 0.436 0.695 — — —
Severe	AD	vs.	
Mild	AD
MMSE 1 0 0.0001* 0 0 15.5 1 1
25	(OH)D3 0.661 0.06 0.019* 0.538 0.785 21.5 0.341 0.969
1,25(OH)2	D3 0.566 0.07 0.333 0.433 0.7 — — —
Severe	AD	vs.	
Moderate 
AD
MMSE 1 0 0.0001* 1 1 10.5 1 1
25	(OH)D3 0.675 0.07 0.014* 0.546 0.804 21.5 0.314 0.969
1,25(OH)2	D3 0.515 0.07 0.836 0.374 0.655 — — —
Total	AD	vs.	
HS
MMSE 0.997 0.003 0.0001* 0.992 1 27.5 1 0.984
25	(OH)D3 0.843 0.03 0.0001* 0.782 0.904 20.5 0.741 0.787
1,25(OH)2	D3 0.455 0.05 0.327 0.366 0.543 — — —
AUC,	area	under	the	ROC	curve;	CI,	confidence	interval;	SE,	standard	error	of	AUC.
aCutoff	values	at	which	optimal	balance	of	sensitivity	and	specificity	can	be	obtained	according	to	Youden’s	index;	Youden’s	Index	can	be	calculated	as	the	
sum of sensitivity plus specificity minus 1 for all possible cutoff points.
*Sig,	significance	of	AUC.
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TABLE  4 Logistic	regression	analyses	for	the	contribution	of	the	individual	and	combined	predictors
β SE Wald Sig. OR
OR 95% CI
CC%Lower Upper
MCI- HS
A-	Univariate
Age 0.033 0.023 1.976 0.16 1.034 0.987 1.082 57.4
Gender −0.197 0.363 0.295 0.587 0.821 0.403 1.672 52.5
MMSE −1.324 0.251 27.858 0.0001* 0.266 0.163 0.435 90.2
25	(OH)D3 −0.146 0.031 22.044 0.0001* 0.864 0.813 0.918 70.2
1,25(OH)2	D3 0.005 0.011 0.251 0.616 1.005 0.985 1.026 50.8
B-	Multivariate
MMSE −1.445 0.295 24.041 0.0001* 0.236 0.132 0.42 88.5
25	(OH)D3 −0.168 0.047 12.644 0.0001* 0.846 0.771 0.927
Mild AD- HS
A-	Univariate
Age 0.033 0.028 1.41 0.235 1.033 0.979 1.091 61.8
Gender −0.509 0.408 1.557 0.212 0.601 0.27 1.337 59.8
MMSE −2.162 0.554 15.22 0.0001* 0.115 0.039 0.341 96.1
25	(OH)D3 −0.188 0.039 22.744 0.0001* 0.829 0.767 0.895 71.6
1,25(OH)2	D3 0.021 0.013 2.578 0.108 1.021 0.995 1.048 61.8
Moderate AD- HS
A-	Univariate
Age 0.133 0.038 12.119 0.0001* 1.143 1.06 1.231 70.8
Gender −0.944 0.446 4.492 0.034* 0.389 0.162 0.931 63.5
MMSE −0.053 846.038 0 0.992 0 0 0 100
25	(OH)D3 −0.178 0.04 20.04 0.0001* 0.837 0.774 0.905 75
1,25(OH)2	D3 0.008 0.016 0.256 0.613 1.008 0.978 1.039 63.5
Severe AD- HS
A-	Univariate
Age 0.048 0.029 2.628 0.105 1.049 0.99 1.111 66.7
Gender −0.811 0.452 3.215 0.073 0.444 0.183 1.078 65.6
MMSE −0.456 397.131 0 0.995 0.086 0 0 100
25	(OH)D3 −0.316 0.069 20.821 0.0001* 0.729 0.636 0.835 78.5
1,25(OH)2	D3 0.012 0.013 0.86 0.354 1.012 0.987 1.037 67.7
All participants
A-	Univariate
Age 0.059 0.021 7.502 0.006* 1.06 1.017 1.106 62.1
Gender −0.735 0.326 5.087 0.024* 0.48 0.253 0.908 63.9
MMSE −0.162 0.554 15.22 0.0001* 0.115 0.039 0.341 97.6
25(OH)D3 −0.213 0.033 41.013 0.0001* 0.808 0.757 0.863 79.9
1,25(OH)2	D3 0.013 0.01 1.635 0.201 1.013 0.993 1.033 63.9
B-	Multivariate
MMSE −2.83 1.022 7.662 0.006* 0.059 0.008 0.438 98.2
25(OH)D3 −0.207 0.173 2.262 0.0018* 0.813 0.579 1.141
β:	Logistic	regression	coefficient;	CC%:	correct	classification	%;	CI:	confidence	interval;	OR:	Odd	ratio	(Exponent	of	β),	Sig:	Logistic	Regression	p values for 
Wald.	Only	significant	variables	are	retained	in	the	B.	Disease	groups	were	tested	against	HS.	Predictor	power	was	evaluated	in	MCI	and	AD	tested	against	
HS.
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5  | CONCLUSION
MMSE	and	25(OH)D3	are	excellent–perfect	predictors	and	diagnostic	
instruments	for	MCI	and	AD.	The	present	study	highlights	the	value	of	
the	combination	of	MMSE	and	25(OH)D3	(but	not	1,25(OH)2D3) as it 
provides	an	overall	98%	prediction	success	rate.	These	results	suggest	
that	MMSE	and	25(OH)D3	could	support	the	clinical	diagnosis	of	MCI	
and	the	mild,	moderate,	and	severe	stages	of	AD.
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